Rockwell Medical: High-Risk Turnaround Hinges on Triferic Platform Amid Heavy Financial Headwinds
Overview
Rockwell Medical, formerly buoyed by record sales and its position as a leading U.S. supplier of dialysis concentrates, has experienced a stark reversal of fortune in 2025. The abrupt loss of its largest customer triggered a 44% revenue plunge and reversed its hard-won profitability. The company is now forced to reckon with a poorly leveraged cost structure and a commoditized core business incapable of supporting meaningful earnings. This leaves the transformative (but highly speculative) Triferic therapeutic as the sole meaningful value driver. While Triferic’s clinical edge offers hope, RMTI’s valuation reflects deep market skepticism and severe operational risk.